Stocks To Buy Now

Blog


DGE 4th KOL & Advanced Practice Providers Forum Attendees to Gather In Philadelphia

Biotech, pharma, and life science companies and professionals are invited to attend the 4th KOL & Advanced Practice Providers Forum, hosted by Dynamic Global Events (“DGE”), in Philadelphia April 29-30th, as an in-person conference with an online streaming option.

A global leader in organizing networking events, DGE focuses on delivering the highest-quality data and networking avenues to the Pharmaceutical, Biotechnology, Medical Device, and Healthcare sectors.

Over the next decade, the Key Opinion Leader (“KOL”) market is expected to grow at a rate of 12.5%. New technology developments have changed baseline expectations for KOL outreach and relationship management, so your team needs to always sharpen its skills with the up-to-the-minute lessons available at this event!

Powerful speakers will share in-depth insights at the DGE forum on how companies can strengthen internal ties for better KOL management and outreach. Stronger internal ties will get better engagement efforts. The company leaders will also talk about compliance among all departments in a company to make the KOL involvement manageable and result oriented.

Senior MSL and engagement directors will share insights on how companies can build their product information and branding around each KOL. Discussions will also be held on how social media can be used to engage the next generation of KOLs.

By popular demand, this year’s all-new agenda provides a special focus on Nurse Practitioners and Physician Assistants, who are essential for working with product information in clinical settings. These DGE conferences offer the medical and life science fraternity a platform to connect with industry associates and gain valuable insights.

To learn more, please visit https://ibn.fm/oPTMg.

From Our Blog

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

May 9, 2025

A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers […]

Rotate your device 90° to view site.